PM
BPMC

Parametrica Management’s Blueprint Medicines BPMC Stock Holding History

Parametrica Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,918
Closed -$251K – 82
2022
Q2 		$251K Buy
+4,918
New +$288K 0.27% 94

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Parametrica Management's BPMC Position: Q3 2022 in Review

Parametrica Management sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 4,918 shares — an estimated $251K sold.

Parametrica Management first reported a position in BPMC in Q2 2022 and held it in 1 quarter. The position peaked at $251K in Q2 2022. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

  • Parametrica Management reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
  • Parametrica Management sold 4,918 Blueprint Medicines shares in Q3 2022, an estimated $251K.
  • Parametrica Management first reported a position in Blueprint Medicines in Q2 2022 and held it in 1 quarter.
  • Parametrica Management's Blueprint Medicines position peaked at $251K in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Parametrica Management's 13F filing for Q3 2022, filed 3 Nov 2022.